Cargando…

Personalised medicine for nonsmall cell lung cancer

After years of standard care prescribed to cancer patients without any selection except the primary site and histology of the tumour, the era of precision medicine has revolutionised cancer care. Personalised medicine refers to the selection of patients for specific treatment based on the presence o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mascaux, Céline, Tomasini, Pascale, Greillier, Laurent, Barlesi, Fabrice
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2017
Materias:	Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489039/ https://www.ncbi.nlm.nih.gov/pubmed/29141962 http://dx.doi.org/10.1183/16000617.0066-2017

Ejemplares similares

Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience
por: Greillier, Laurent, et al.
Publicado: (2016)

Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?
por: Boyer, Arnaud, et al.
Publicado: (2018)

EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer
por: Tomasini, Pascale, et al.
Publicado: (2016)

First-line pembrolizumab in programmed death ligand 1 positive non-small cell lung cancer
por: Travert, Camille, et al.
Publicado: (2019)

Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases
por: Tomasini, Pascale, et al.
Publicado: (2019)

Bronchoscopic treatment of inoperable nonsmall cell lung cancer
por: Kniese, Christopher M., et al.
Publicado: (2020)

How to handle oligometastatic disease in nonsmall cell lung cancer
por: Eichhorn, Florian, et al.
Publicado: (2021)

New developments in locally advanced nonsmall cell lung cancer
por: Huber, Rudolf M., et al.
Publicado: (2021)

The Value of Population Screening in Advancing Personalized Medicine in the Field of Lung Cancer
por: Mogenet, Alice, et al.
Publicado: (2021)

Personalised medicine in interstitial lung diseases: Number 6 in the Series “Personalised medicine in respiratory diseases” Edited by Renaud Louis and Nicolas Roche
por: Kokosi, Maria A., et al.
Publicado: (2018)

Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer
por: Abdayem, Pamela, et al.
Publicado: (2021)

Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients
por: Barlesi, Fabrice, et al.
Publicado: (2017)

Machine Learning for Prediction of Immunotherapy Efficacy in Non-Small Cell Lung Cancer from Simple Clinical and Biological Data
por: Benzekry, Sébastien, et al.
Publicado: (2021)

Personalised medicine in asthma: time for action: Number 1 in the Series “Personalised medicine in respiratory diseases” Edited by Renaud Louis and Nicolas Roche
por: Chung, Kian Fan
Publicado: (2017)

Chemotherapy and immune checkpoint inhibitor combination, a new standard in squamous non-small cell lung cancer?
por: Travert, Camille, et al.
Publicado: (2020)

Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era
por: Savale, Laurent, et al.
Publicado: (2018)

Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapy
por: Jean, Fanny, et al.
Publicado: (2017)

Personalised pulmonary rehabilitation in COPD
por: Wouters, Emiel F.M., et al.
Publicado: (2018)

Personalised medicine in sleep respiratory disorders: focus on obstructive sleep apnoea diagnosis and treatment
por: Bonsignore, Maria R., et al.
Publicado: (2017)

Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer
por: Mogenet, Alice, et al.
Publicado: (2023)

Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens: Number 2 in the Series “Pathology for the clinician” Edited by Peter Dorfmüller and Alberto Cavazza
por: Bubendorf, Lukas, et al.
Publicado: (2017)

Personalising lung cancer screening: An overview of risk‐stratification opportunities and challenges
por: ten Haaf, Kevin, et al.
Publicado: (2021)

Revisiting Bevacizumab + Cytotoxics Scheduling Using Mathematical Modeling: Proof of Concept Study in Experimental Non‐Small Cell Lung Carcinoma
por: Imbs, Diane‐Charlotte, et al.
Publicado: (2017)

Modern therapies of nonsmall cell lung cancer
por: Jachowski, Andrzej, et al.
Publicado: (2023)

The Possibility of Traditional Chinese Medicine as Maintenance Therapy for Advanced Nonsmall Cell Lung Cancer
por: Xu, Weiru, et al.
Publicado: (2014)

TP53 Mutations in Nonsmall Cell Lung Cancer
por: Mogi, Akira, et al.
Publicado: (2011)

Signatures of Drug Sensitivity in Nonsmall Cell Lung Cancer
por: Gong, Hua C., et al.
Publicado: (2011)

The Role of Proteasome Inhibition in Nonsmall Cell Lung Cancer
por: Escobar, Mauricio, et al.
Publicado: (2011)

Gemcitabine for the treatment of advanced nonsmall cell lung cancer
por: Toschi, Luca, et al.
Publicado: (2009)

Thyroid Metastasis from Nonsmall Cell Lung Cancer
por: Namad, Tariq, et al.
Publicado: (2013)

An IMRT/VMAT Technique for Nonsmall Cell Lung Cancer
por: Zhao, Nan, et al.
Publicado: (2015)

Impacts of lung and tumor volumes on lung dosimetry for nonsmall cell lung cancer
por: Lei, Weijie, et al.
Publicado: (2017)

Pemetrexed-associated Ischemic Colitis in Nonsmall Cell Lung Cancer
por: Ye, Liang, et al.
Publicado: (2017)

Oligometastatic Disease at Presentation or Recurrence for Nonsmall Cell Lung Cancer
por: Gomez, Daniel R., et al.
Publicado: (2012)

Radiofrequency Ablation for Early-Stage Nonsmall Cell Lung Cancer
por: Hiraki, Takao, et al.
Publicado: (2014)

Pattern of bone metastasis in patients with nonsmall cell lung cancer
por: Miyazaki, Kunihiko, et al.
Publicado: (2018)

Disparate outcomes in nonsmall cell lung cancer by immigration status
por: Chau, Brittney, et al.
Publicado: (2021)

Therapeutic options targeting angiogenesis in nonsmall cell lung cancer
por: Crinò, Lucio, et al.
Publicado: (2014)

Personalised Medicine in Europe
por: Andriukaitis, Vytenis
Publicado: (2017)

Personalising cancer medicine with prognostic markers
por: Kerr, David J, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_prerbn6ku0etlkulnert58ltjh